Eli Lilly
6 articlesVisitors can use the page to follow sector analysis, sector exposure and fund ownership, review examples and see how public companies changes the way a product, rule, account or market signal should be interpreted.
Lilly's New Weight-Loss Pill Targets Millions Avoiding Injections
Eli Lilly's once-daily pill Foundayo just won U.K. approval for obesity and diabetes, opening a market of patients who have resisted injectable drugs and intensifying competition with Novo Nordisk in a fast-growing sector
Eli Lilly's Global Obesity Drug Ambitions May Outpace U.S. Sales
Eli Lilly's latest earnings beat expectations, but Bank of America now sees the company's international obesity drug market as a bigger long-term driver than U.S. demand, raising new questions for investors
Novo Nordisk Stock Drops After Heart Drug Trial Misses Key Target
Novo Nordisk shares tumbled after its heart drug Ziltivekimab failed a major late-stage trial, raising questions about the company's growth beyond weight-loss drugs and triggering a sharp market reaction
Eli Lilly's Soaring Stock Tests the 'Own, Don't Trade' Philosophy
Eli Lilly's stock has surged nearly 400% in five years, but with shares now above $1,150, investors face a key question: does the long-term case still hold, or is it time to rethink the classic buy-and-hold approach
UBS Hikes Eli Lilly Target as Prescription Data Clouds Outlook
UBS raised its price target for Eli Lilly to $1,425, outpacing other Wall Street banks, but new prescription data and high expectations ahead of earnings add risk for investors holding LLY shares into August
Biotech Stocks Outpace Tech as M&A Wave Reshapes 2026 Market
Biotech stocks are leading the market in 2026, fueled by a surge in acquisitions and a shift in regulatory policy. Investors are weighing whether the rally can continue as valuations climb and deal activity accelerates